Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nuke, try this. it's a different form but without charts. I'll try to find the original doc that Sarissa filed. But in the meantime, you get the idea of how the fight is done and what is probably been transpiring between Amarin and Sarissa for the past year.
https://www.sec.gov/edgar/search/?r=el#/q=sarissa&dateRange=10y&category=form-cat0&ciks=0001080014&entityName=Innoviva%252C%2520Inc.%2520(CIK%25200001080014)
Monk I love pierogis but roasted chicken hearts?????
My polish friend showed me how to make them with farmers cheese tons of butter, the shell was thin filled with cheese then soaked in sauteed onions in butter of course.
If anyone is looking to read about the "Denner" in action then please read this proxy filed by Sarissa. It's actually quite entertaining. I can imagine the Denner crew ripping apart Amarin's business model. LOL
https://investor.inva.com/node/16991/html
MMS. I believe one of the 3 people who signed the EPADI letter called and claimed the person who they spoke to said they are in the process of. I don't believe there was anything in writing actually I'm surprised that someone at Denner's office actually spoke to this person. There was a post on stocktwits that made the statement about the conversation. I recall the post cause I didn't believe it was real but someone corrected me then the EPADI letter was released and posted on Ihub. Long winded but I'm procrastinating cause I don't want to start cooking for tomorrow...LOL
rosemount, there are definitive rules that are required to move forward with overriding the corporate bylaws and charters of a public company. It's serious business and must be followed to the tee or the documents will be rejected by the SEC or FINRA whatever dept oversees proxy fights. Submitting filings to the SEC is a painful exercise and to receive final approval you have to jump through hoops. Then if it takes too long the dated documents expire then you have to start over it can take months to receive approval I think in this case because of the new Universal Proxy rules they will be exceptionally scrutinized.
capt, I think the company is stalling for time by ignoring Sarissa's attempt to introduce his selected board members. I believe the BOD of AMRN know their time is limited. There's a pecking order of time that has to be followed. Sarissa released their intentions on Oct 11, 2022 Amarin released their "mea culpa" PR the same day Sarissa announced that they will move forward with a Special Meeting 10/11/22. Since when does Amarin ever release their intentions exactly the same day as a come back to defend themselves from the "enemy"? NEVER. and the EPADI letter followed on 10/17/22. Ten 10 days later Amarin appoints 2 new board members and 2 old timers get sacked.
So if Sarissa goes the route of using the new Universal Proxy Rules they have to notify Amarin 60 days prior to the last Annual Meeting date which was June 27, 2022. Then Sarissa needs to transmit their intentions electronically to the company no later than 60 calendar days which would bring it to April 29, 2023.
So worst-case scenario we should know by April 2023 who Denner intends to place on the board...... it's going to be a long winter ;-(
STS, it took 10 yrs to get V FDA approved blah blah and one story to discredit the 10 yrs. written by a bunch of hoodlums.
gozips, thanks, glad to hear they're being proactive. It's a real wake up call for Bridgewater to start defending their one and only product!!!
I hope ppl can open this wsj link. It explains how PBM get in the middle of drug pricing it's awful!
https://www.wsj.com/articles/elon-musk-bernie-sanders-and-others-miss-the-mark-over-pricey-insulin-11669000489?st=l7i227lbvmese4e&reflink=desktopwebshare_permalink
raf, thanks for all you do.
Has anyone heard from the disastrous IR dept. Lisa person???
raf, why is the article still listed? Did I miss something?
https://www.sciencedirect.com/search?qs=vascepa
orbapu, the article that was supposed to be removed is still listed.????
https://www.sciencedirect.com/search?qs=vascepa
gozips, may I suggest that when you send IR or KM any correspondence you cc Sarissa/Denner. They are trying to keep Denner away from Amarin and pretend that they are being responsive to the shareholder's emails. I've found if you cc Denner they will reply so it appears that they actually are interested in what we have to say.
raf, see below information about one of the authors Noora Alhajri. This statement is from an acquaintance. Maybe coincidence???
Noora AlHajri, M.D., MPH
PGY1 Internal Medicine Resident at Cleveland Clinic Abu Dhabi
She cannot be located on the website of the clinic. I am trying to reach a doctor I know who works there to ask about her. Hoping for a slip of the tongue.
here's another lame description of Icosapent Ethyl. Springmeds is an online pharmacy located in IL. Price for the GV $168.80=120 capsules.
https://www.springmeds.com/productdetails/Vascepa-Icosapent-Ethyl?uidtype=group&form=Capsules&isGeneric=Y&strength=1gm
ORBAPU, I recall JL when I first got involved with Amarin. I don't recall his discussion about meta research.
Thanks
concapk, please see the slide explaining the progression of stages in each country see Germany with 2**. At the bottom of the page there's a footnote please note 2** referencing the status of Germany. It's over, gone, kaput.... moving on!
https://www.sec.gov/Archives/edgar/data/897448/000119312522286778/d408505dex991.htm
raf, thanks great find and follow up. I had NO idea this type of slander is published in "peer review" open access journals. Slimy to say the least.
ORBAPU, Unfortunately, I have a feeling the damage is done. A retraction may get released but once this BS gets out in the public domain it's hard to undo. Especially since this "publication" is read throughout the EU and has a global distribution. I wonder who was behind this BS.
raf, Elsevier Ltd. see below.
Is Elsevier predatory?
Scientific and academic publisher Reed Elsevier released six journals that were found to feature falsified peer reviews. These peer reviews were paid for by pharmaceutical companies, including pharma giant Merck. Elsevier has also been involved in other scandals, including being accused of publishing racist content.
jroon, Thanks, I didn't realize the link wasn't functional.
swg, how about someone posting on twitter??? I don't have many followers...someone who has should post it. What do you think..any takers?
found this on LinkedIn, apologies if it's been posted.
https://www.linkedin.com/pulse/our-response-letter-editor-regarding-article-effects-john%3FtrackingId=49ToT%252BVzR9aD27xlKk1cLQ%253D%253D/?trackingId=49ToT%2BVzR9aD27xlKk1cLQ%3D%3D
CBB, who is TPL?
CBB I'll tell you why KM doesn't want to open the books to Denner. He'll find out that some of their statements in financials are BS.
CBB, oh btw we can forget Edding. I was impressed that Sequoia was one of the investors in Edding. NOPE they invested in FTX. Stupid money. I no longer believe Eddingpharm is real just like Biologix is real. It's a joke. The only thing real in Amarin is vascepa. A one product company it needs to be sold asap.
ILT, LOL where's Fauci when we need him? He's a fraud but not as despicable as SBF. The jab gets you an inflamed heart and VJ FTX/SBF gives you empty pockets.
robin, no it doesn't change the percentage of Denner's ownership. The shares are still outstanding. Someone bought 15mill of those shares and whoever didn't buy the shares helped push the price down to where we are today. It's basically a supply and demand function of a free market. Price discovery.
Until something happens to shake up the company the stock will linger in a tight range. Denner where are you???
North, read the slide where it mentions progress in the EU the German footnote has 2**read the bottom of slide with the explanation of the 2** for Germany. They're history
CBB, It means we can ditch the possible approval in Germany. They're history. Too bad they would have been one of the largest revenue generating countries.
raf, maybe cause KM made forward looking projections. I must agree it is unusual.... maybe it's a transparency thing. Actually it's about time they provide some guidance for the next several quarters. We've been left in the dark for too long.
LBL, you got that one right. Since Sarissa announced a year ago they started buying stock. In the past year, certain events have taken place that were a dead giveaway. First Sofinnova sold entire holdings, Lars steps down as COB then retires and BB sold over 15mill leaving only 5 mill shares in their fund. The selling pressure should ease up on the share price. I'm wondering if Sarissa will file their proxy under the new Universal Proxy. Hopefully, they're not going to wait for Amarin to file their preliminary proxy which won't be for at least 7 months. The ball is in Denner's court game, set, match. I hope.
jroon, yeah just like the Biologix agreement from 2016. I think it's all air. They need to accept Denner's proposals and welcome him to the board so he can package the company and sell it!!!
babr, check out the ingredients contained in one gv (Hikma) capsule....no wonder your body rejected it.
ICOSAPENT ETHYL
icosapent ethyl capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0054-0508
Route of Administration ORAL
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ICOSAPENT ETHYL (UNII: 6GC8A4PAYH) (ICOSAPENT - UNII:AAN7QOV9EA) ICOSAPENT ETHYL 1 g
Inactive Ingredients
Ingredient Name Strength
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
GLYCERIN (UNII: PDC6A3C0OX)
SORBITOL (UNII: 506T60A25R)
.ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1) 2 mg
AMMONIA (UNII: 5138Q19F1X)
FERROSOFERRIC OXIDE (UNII: XM0M87F357)
ISOPROPYL ALCOHOL (UNII: ND2M416302)
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
POLYVINYL ACETATE PHTHALATE (UNII: 58QVG85GW3)
ALCOHOL (UNII: 3K9958V90M)
ETHYL ACETATE (UNII: 76845O8NMZ)
SORBITAN (UNII: 6O92ICV9RU)
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
Product Characteristics
Color YELLOW Score no score
Shape CAPSULE Size 25mm
Flavor Imprint Code 54;648
Contains
Packaging
johnhan, yup out with the old and in with the new. Sofinnova is gone and BB will be gone as well. There's a formula as to how many shares a fund can sell depends on daily volume vs how many shares they own. It's just a matter of time before they sell all Amarin's shares and good riddance to the overhang.
so since 2015 they entered into the Edding agreement. Does anyone think this is real???? 7 years later NADA.
This was from 1st Q 2015.
How discussed am I with Amarin's BS? Denner is our only hope to save Vascepa from going down the tubes.
*We are dependent upon our collaboration with Eddingpharm to commercialize Vascepa in certain regions outside of the United States, and if Vascepa fails to successfully fulfill its obligations, or is ineffective in its commercialization of Vascepa in the China Territory, or if our collaboration is terminated, our plans to commercialize Vascepa outside of the United States may be adversely affected.
In February 2015, we entered into the DCS Agreement with Eddingpharm, under which we granted exclusive rights to Eddingpharm to develop and commercialize Vascepa in the China Territory. We are dependent on Eddingpharm for certain regulatory filings outside of the United States with respect to Vascepa and the commercialization of Vascepa outside of the United States. If Eddingpharm fails to perform its obligations under the DCS Agreement or is ineffective in its commercialization of Vascepa in the China Territory or if we fail to effectively manage our relationship with Eddingpharm, our ability to and the extent to which we commercialize and obtain certain regulatory approvals of Vascepa outside of the United States would be significantly harmed.
In addition, Eddingpharm has the right to terminate the agreement under certain conditions. If Eddingpharm terminates the DCS Agreement, we would be required to either enter into alternative arrangements with third parties to commercialize Vascepa in the China Territory, which we may be unable to do, or to increase our internal infrastructure, both of which would likely result in significant additional expense and delay or termination of our Vascepa clinical development programs outside of the United States.
For all you people who think the BB lost money think again. They are bailing cause they no longer have insider info since Lars is leaving as of 12/2022.
They bought in at .15cents. Ha Ha they made a bundle since then. They are not our friends.
https://www.sec.gov/Archives/edgar/data/897448/000119312515124231/d907632ds3.htm
FYI, BTW this is all BS.
Biologix FZCo
In March 2016, the Company entered into an agreement with Biologix FZCo (“Biologix”), a company incorporated under the laws of the United Arab Emirates, to register and commercialize Vascepa in several Middle Eastern and North African countries. Under the terms of the distribution agreement, the Company granted to Biologix a non-exclusive license to use its trademarks in connection with the importation, distribution, promotion, marketing and sale of Vascepa in the Middle East and North Africa territory. Upon closing of the agreement, the Company received a non-refundable up-front payment, which will be recognized as revenue over 10 years commencing upon first marketing approval of Vascepa in the territory. The Company is entitled to receive all payments based on total product sales and pays Biologix a service fee in exchange for its services, whereby the service fee represents a percentage of gross selling price which is subject to a minimum floor price.